Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS.
Fajgenbaum DC, et al. Among authors: kambayashi t.
J Clin Invest. 2019 Aug 13;129(10):4451-4463. doi: 10.1172/JCI126091.
J Clin Invest. 2019.
PMID: 31408438
Free PMC article.